AXSM vs. PBH, INSM, BHVN, RARE, CBAY, HCM, FOLD, BHC, XENE, and CRNX
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Prestige Consumer Healthcare (PBH), Insmed (INSM), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), CymaBay Therapeutics (CBAY), HUTCHMED (HCM), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical preparations" industry.
Prestige Consumer Healthcare (NYSE:PBH) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
Prestige Consumer Healthcare has higher revenue and earnings than Axsome Therapeutics. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.
Prestige Consumer Healthcare received 63 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave Prestige Consumer Healthcare an outperform vote while only 68.46% of users gave Axsome Therapeutics an outperform vote.
Prestige Consumer Healthcare has a net margin of -7.11% compared to Prestige Consumer Healthcare's net margin of -88.41%. Axsome Therapeutics' return on equity of 14.09% beat Prestige Consumer Healthcare's return on equity.
Prestige Consumer Healthcare presently has a consensus price target of $110.00, indicating a potential upside of 53.33%. Axsome Therapeutics has a consensus price target of $122.00, indicating a potential upside of 65.56%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Prestige Consumer Healthcare.
Prestige Consumer Healthcare has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
In the previous week, Axsome Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 9 mentions for Axsome Therapeutics and 8 mentions for Prestige Consumer Healthcare. Axsome Therapeutics' average media sentiment score of 0.84 beat Prestige Consumer Healthcare's score of 0.40 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.
100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 1.6% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 24.5% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Prestige Consumer Healthcare beats Axsome Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
